EGFR and colorectal carcinoma: Current pharmacological approaches for optimizing CRC management include non-specific drugs, such as fluoropyrimidines, irinotecan, and oxiplatin, as well as targeted drugs, such as bevacizumab, angiogenesis inhibitors, cetuximab, epidermal growth factor receptor (EGFR) inhibitors, regorafenib, and multikinase inhibitors (7, 9, 10).